Philippe Lamoureux – Director, LEEM, France
Philippe Lamoureux, director of LEEM, the pharmaceutical industry’s association in France, reflects on the winds…
Leem is comprised of decision-making bodies (General Assembly, Board of Directors, Board President) and research bodies (Committees, Board, strategic implemention agencies).
Over 300 drug companies operate in France. They employ nearly 100,000 people and creat 550 new jobs per year while invest annually approximately 3.9 billion euros in research of new drugs.
The companies represented by the Leem realize 98.7% of the activity of the drug in France.
Worldwide (USA, Europe and Japan), more than 60 billion euros are spent each year by pharmaceutical companies to research and develop innovative new treatments. Drug companies are dedicated to creating and developing new medicines and vaccines for human use, for serious diseases related to the welfare and conditions of everyday life. The role of Leem is to develop and enforce the ethics of the profession, to facilitate trade between its members, to defend their collective interests and to strengthen links with other health professions.
Address: 58 Boulevard Gouvion Saint-Cyr, 75017 – Paris
Tel: +33 (0)1 45 03 88 88
Web: http://www.leem.org/
Philippe Lamoureux, director of LEEM, the pharmaceutical industry’s association in France, reflects on the winds…
The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association,…
The General Manager of LEEM talks about the association’s strategy based on three key points, innovation,…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A…
Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes…
What are the main tasks of the LEEM? The LEEM is the only professional organization representing the…
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for…
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19…
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how…
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in…
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA…
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679…
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…